Postnatal Inflammatory Rat Model for Cerebral Palsy: Too Different from Humans
Overview
Affiliations
Objective: In humans, cerebral palsy (CP) may originate from inflammation during the second and third trimesters of gestation when preoligodendrocytes (Pre-OL) are most vulnerable to an inflammatory insult. We studied a postnatal CP model to evaluate injury that would correlate with presence of Pre-OL in human pregnancy.
Study Design: On postnatal (P) days 2, 3, 4, 5 and 6, pups were treated with (lipopolysaccharide [LPS]) (n = 7; 30, 30, 60, 60, 120 microg/Kg) or saline (n = 7). Neonates were tested for motor and cognitive development. Adult offspring performed beam walking and rotarod for motor activity. White matter damage was assessed with immunohistochemical Pre-OL markers (CNP, PLP). Statistical analysis included Mann-Whitney U and analysis of variance.
Results: LPS-treated animals performed negative geotaxis (P = .009) and surface righting (P = .01) earlier than controls. No differences were observed for other neonatal tests. Adult LPS-treated offspring performed better in tests of motor control: rotarod (P = .01) and beam walking (P = .02). Pre-OL markers were altered in LPS-treated animals at both P22 (CNP and PLP increased in LPS, P < .01 and P < .001, respectively) and 12 weeks (CNP and PLP decreased in LPS, P < .0001 and P < .03, respectively).
Conclusion: Neonatal exposure to LPS induced white matter damage in the brain, accelerated neurodevelopment and motor tasks in adulthood. These are similar to findings from a postnatal hypoxic model suggesting that in the rodent, targeting the Pre-OL does not result in a CP phenotype.
Zhang J, Li M, Wang C, Xu Q, Zhang S, Zhu Y Zhongguo Dang Dai Er Ke Za Zhi. 2024; 26(4):394-402.
PMID: 38660904 PMC: 11057307. DOI: 10.7499/j.issn.1008-8830.2310081.
Goracke-Postle C, Burkitt C, Panoskaltsis-Mortari A, Ehrhardt M, Wilcox G, Graupman P BMC Neurol. 2021; 21(1):384.
PMID: 34607558 PMC: 8489087. DOI: 10.1186/s12883-021-02333-2.
Pires J, Foresti M, Silva C, Rego D, Calio M, Mosini A Front Cell Neurosci. 2020; 14:142.
PMID: 32581717 PMC: 7283979. DOI: 10.3389/fncel.2020.00142.
Cavarsan C, Gorassini M, Quinlan K J Neurophysiol. 2019; 122(3):1238-1253.
PMID: 31411933 PMC: 6766736. DOI: 10.1152/jn.00233.2019.
Fragopoulou A, Qian Y, Diaz Heijtz R, Forssberg H Mol Neurobiol. 2019; 56(10):6883-6900.
PMID: 30941732 PMC: 6728419. DOI: 10.1007/s12035-019-1548-8.